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Bladder cancer is the fourth most common cancer in men and the tenth most common in women, and while long-term survival is more predominant compared to other common cancers, more than 47% percent of bladder cancer deaths could have been avoided with an early diagnosis (Verma et al., http://dx.doi.org/10.1148/ rg.322115125). Initial diagnosis is generally made via cystoscopy, but magnetic resonance imaging (MRI) can be considered superior due to higher soft-tissue contrast that can detect small tumors and increased accuracy in determining the extent of muscle invasion. The Thompson Group has used fi bronectin attachment protein (FAP) to target liposomes to bladder tumor cells.
To expound upon this previous work, we designed a synthetic pathway for a peptide-targeted MRI contrast agent and have made signifi cant progress toward the fi nal construct, which is composed of HP-β-CD threaded onto a polymer core and further modifi ed with Gd-DOTA and a maleimide linker to attach the FAP peptide.
This type of construct is called a polyrotaxane (PR), and we have shown that PRs whose CDs have been modifi ed with Gd-DOTA have a high relaxivity and extended contrast in various organs. New preparation and attachment methods for the maleimide linker are under investigation, as is the most effective coupling method for the FAP peptide. Subsequent studies will include cell culture, relaxivity measurements, and in vivo MR imaging with mice to determine the agent's targeting and contrast enhancement abilities. 
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A cartoon depiction of polyrotaxane formation. Hydroxypropyl-β-cyclodextrin units are threaded onto the polymer core akin to beads being threaded onto a string, followed by an endcapping reaction to prevent dethreading. The polyrotaxane is further modi ed with Gd-DOTA and the targeting FAP peptide to produce the MR contrast agent.
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